[Definition of therapeutic effect of mildronate in patients with chronic heart failure].
In developed countries chronic heart failure (CHF) is one of the main reasons of death and physical disability. CHF affects approximately 1-2% of the population and its prevalence is still increasing. Today ACE inhibitors, beta-blockers, diuretics are the first line drugs in treatment of CHF. Mildronate is a new drug optimizing cardiac energy metabolism and could be an effective approach in CHF patients' management. The aim of the study was to investigate the efficacy and safety of mildronate in treatment of CHF (NYHA III-IV funct. class) patients. 110 patients with CHF, stable on conventional treatment (diuretics, ACE inhibitors, beta-blokers, digoxin), were treated additionally with mildronate. Assessment was performed with clinical data, FC change, ECO-cardiography, 6-minute walk test. Mildronate showed to be an effective drug in complex treatment of chronic heart failure.
National Centre of Therapy, Tbilisi, Georgia.
V
V
Chumburidze
T
T
Kikalishvili
T
T
Sulashvili
D002303:Cardiac Output, Low / Q000188:drug therapy*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate